Mesa Labs (MLAB): Debts to Book Capitalization

Mesa Laboratories, Inc. (MLAB) price action is supported by a steady inflow of funds from the sale of medical consumables, where the current figure stands at 0.83. The business generates revenue by creating high-precision monitoring systems for biopharmaceutical transportation, minimizing the risk of cargo spoilage. The company's growth is based on the aggressive acquisition of small specialized firms, which are rapidly integrated into the holding's overall operating model.

MLAB Mesa Laboratories, Inc. Debt to Book Value Ratio (07/04/2022 - 10/28/2026)

Summary analytical data breakdowns for Mesa Laboratories Inc (MLAB)

- price and consensus price forecast:

Stock Price Mesa Laboratories, Inc.|MLAB - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Mesa Laboratories Corp.|MLAB - Full Takeover Company Value

- book capitalization data:

Net Assets per Single Share Mesa Labs|MLAB - Accounting Capitalization|Market Value to Book Value Ratio mesalabs.com|MLAB - Company Assets

- debt and liquidity data:

Debt to Equity Mesa Laboratories, Inc.|MLAB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Mesa Labs Corp|MLAB - Company Cumulative Indebtedness|Debts to Book Capitalization Mesa Laboratories Corp.

Fundamental company analysis:Mesa Laboratories, Inc.

Investors assess capital resilience by analyzing the debt load relative to the company's equity. Amid geopolitical risks and chip supply chain disruptions for Mesa Laboratories, Inc. (MLAB), the ratio of borrowed funds to balance sheet capitalization determines the business's degree of financial autonomy. A decrease in this ratio confirms asset protection, whereas excessive conservatism may limit the growth rate of return on investment.

Competitors of Mesa Laboratories, Inc.